ER 68203Alternative Names: ER 68203-00; ER-68203
Latest Information Update: 17 Nov 2006
At a glance
- Originator Eisai Co Ltd
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Integrin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Apr 2003 No development reported - Preclinical for Cancer in Japan (PO)
- 01 Aug 2000 Preclinical development for Cancer in Japan (PO)